---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001955"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:38:30.348200+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences reports ~$137M cash, outlines 2026 clinical milestones for HBV and DMD programs

## Summary
- Preliminary cash ~$137M as of Dec 31, 2025; cash runway expected through 2028.
- PBGENE-HBV: Phase 1/2a ELIMINATE-B dosing Cohorts 3-5 ongoing; additional biopsy data expected H1 2026.
- PBGENE-DMD: IND clearance expected Q1 2026; first patient dosing late-Q1/early-Q2 2026; initial data by year-end 2026.
- Partnered programs: iECURE ECUR-506 RMAT designation; Imugene milestone $8M received; TG Therapeutics potential $7.5M milestone.

## SEC filing metadata
- accession: 0001628280-26-001955
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000162828026001955/0001628280-26-001955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000162828026001955/dtil-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001955
- JSON: https://secwatch.observer/filing/0001628280-26-001955.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.